Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miranda Roberto N, Aladily Tariq N, Prince H Miles, Kanagal-Shamanna Rashmi, de Jong Daphne, Fayad Luis E, Amin Mitual B, Haideri Nisreen, Bhagat Govind, Brooks Glen S, Shifrin David A, O'Malley Dennis P, Cheah Chan Y, Bacchi Carlos E, Gualco Gabriela, Li Shiyong, Keech John A, Hochberg Ephram P, Carty Matthew J, Hanson Summer E, Mustafa Eid, Sanchez Steven, Manning John T, Xu-Monette Zijun Y, Miranda Alonso R, Fox Patricia, Bassett Roland L, Castillo Jorge J, Beltran Brady E, de Boer Jan Paul, Chakhachiro Zaher, Ye Dongjiu, Clark Douglas, Young Ken H, Medeiros L Jeffrey
Аннотация
PATIENTS AND METHODS: We reviewed the literature for all published cases of breast implant-associated ALCL from 1997 to December 2012 and contacted corresponding authors to update clinical follow-up.
RESULTS: The median overall survival (OS) for 60 patients was 12 years (median follow-up, 2 years; range, 0-14 years). Capsulectomy and implant removal was performed on 56 of 60 patients (93%). Therapeutic data were available for 55 patients: 39 patients (78%) received systemic chemotherapy, and of the 16 patients (28%) who did not receive chemotherapy, 12 patients opted for watchful waiting and four patients received radiation therapy alone. Thirty-nine (93%) of 42 patients with disease confined by the fibrous capsule achieved complete remission, compared with complete remission in 13 (72%) of 18 patients with a tumor mass. Patients with a breast mass had worse OS and progression-free survival (PFS; P = .052 and P = .03, respectively). The OS or PFS were similar between patients who received and did not receive chemotherapy (P = .44 and P = .28, respectively).
CONCLUSION: Most patients with breast implant-associated ALCL who had disease confined within the fibrous capsule achieved complete remission. Proper management for these patients may be limited to capsulectomy and implant removal. Patients who present with a mass have a more aggressive clinical course that may be fatal, justifying cytotoxic chemotherapy in addition to removal of implants.